


BEHCET'S DISEASE

What is Behcet's disease?



Behcet's disease is a multisystem inflammatory disorder that causes blood vessel inflammation (vasculitis) characterized by neutrophilic infiltration in the blood vessels around affected tissues

- The most common disease manifestations include ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes (uveitis)
- Behcet's disease can impact almost every organ system including joints, blood vessels, the central nervous system and the digestive tract
- There is significant heterogeneity in how the disease presents, with some patients having mild disease while others are more severely afflicted
- The prevalence of the disease in the United States is ~18k patients, and there is a much higher prevalence in Turkey, Japan and other Asian countries



How is Behcet's disease diagnosed?

The diagnosis of Behcet's disease can be challenging. The International Criteria for Behcet's disease assigns a score to the following manifestations:

- Skin lesions (including oral aphthous and genital ulcers)
- Ocular lesions
- Central nervous system involvement
- Vascular manifestations

Connect with us and learn more



@AristeaTX



Aristea Therapeutics



www.aristea.tx.com

BEHCET'S DISEASE

What causes Behcet's disease?



The cause of Behcet's disease has not been fully elucidated although it is believed that complex interactions between T cells, neutrophils and antigen presenting cells (APCs) are involved in the pathogenesis of Behcet's disease

- Epidemiological data suggest the involvement of both genetic and environmental factors in the development of Behcet's disease



What are the available treatments for Behcet's disease?

- The first line therapy for Behcet's disease patients with mucocutaneous disease is colchicine
- Apremilast (Otezla) was approved for the treatment of oral Behcet's disease in the United States in 2019
- Despite Otezla's availability, physicians that treat Behcet's disease still identify a significant unmet medical need that needs to be addressed with the development of new therapies

Aristea's Clinical Trial: RIST4721-231



RIST4721-231 is a randomized, double-blinded, placebo-controlled, Phase 2a study to evaluate the efficacy and safety of RIST4721 in subjects with Behcet's disease

Connect with us and learn more



@AristeaTX



Aristea Therapeutics



www.aristeatx.com